Jinan Zhuocheng Bio-Tech Co., Ltd.

Active Pharmaceutical Ingredients (APIs) are the active components responsible for the pharmacological effects of medicines. They also play a critical role in determining finished product quality, controlling manufacturing costs and maintaining supply chain stability. From compound design and laboratory research to regulatory approval and large-scale manufacturing, an API typically passes through several stages, including laboratory development, small-scale trials, pilot-scale production, regulatory compliance preparation, registration and approval, and commercial manufacturing. Each stage builds on the previous one and contributes to the successful industrialization of the product and its continued supply to the market.

An API is a substance that produces the intended pharmacological activity in a medicinal product and is used for the prevention, treatment or diagnosis of disease, or to modify physiological functions. Pharmaceutical dosage forms, such as tablets, capsules and injections, are generally composed of APIs and pharmaceutical excipients. The API is the component primarily responsible for the product's therapeutic effect.

Based on their sources and manufacturing processes, APIs can generally be classified into three categories: chemically synthesized APIs, fermentation-derived or biotechnology-based APIs, and naturally extracted APIs. Examples include certain antibiotics and antihypertensive agents produced through chemical synthesis or fermentation, insulin and some peptides manufactured using biotechnology, and active ingredients obtained through the extraction of natural products. From a commercial and market perspective, APIs are also commonly categorized as bulk APIs, specialty APIs, and APIs associated with patented or innovative medicines. These classifications reflect differences in market positioning, technical requirements and commercialization models rather than a single statutory classification.

Within the pharmaceutical supply chain, API manufacturing connects upstream fine chemicals, biological raw materials and intermediates with downstream finished dosage form production. API quality, purity, impurity profiles and batch-to-batch consistency can all have a significant impact on the quality and safety of finished medicines. China is one of the world's major API manufacturing and export bases. Its industry is gradually moving beyond bulk products toward specialty APIs, higher-value products, innovative drug development services and more sophisticated international markets.

The development of an API from the laboratory to commercial manufacturing generally involves six key stages: laboratory research, small-scale trials, pilot-scale production, regulatory compliance preparation, registration and approval, and industrial-scale manufacturing. Process development and quality management extend across multiple stages, while regulatory approval determines whether a product can enter its intended market in accordance with applicable requirements.

Laboratory research is the starting point of API development. Its primary objectives are to identify the target compound, explore a feasible synthesis or preparation route, and obtain sufficient samples for structural confirmation, physicochemical characterization and relevant pharmacological evaluation. Techniques such as distillation, recrystallization and chromatography may be used to isolate and purify laboratory samples. At this stage, the priority is not production volume but understanding the compound and assessing the feasibility of its preparation. Key activities include evaluating potential intellectual property risks and production costs associated with the proposed route, designing and completing the synthesis of the target compound, confirming its chemical structure, measuring relevant physicochemical parameters and gaining an initial understanding of its stability and general properties. These findings provide the basis for subsequent process development.

Once a target compound demonstrates sufficient development potential, the project moves into small-scale trials. The main objective is to transform the laboratory synthesis route into a process with potential for industrial application. Through repeated synthesis and data collection, researchers gradually establish a production route suitable for further scale-up.

During this stage, laboratory procedures that are unsuitable for industrial manufacturing need to be identified and improved. Researchers also evaluate how industrial-grade raw materials and solvents affect reaction performance and product quality, and optimize reaction conditions to balance product quality, yield and manufacturing costs. In addition, recovery and reuse methods for raw materials, solvents and other recyclable materials should be investigated to improve resource efficiency and reduce costs. The selection and optimization of the process route should also take into account the use of toxic or hazardous substances, the generation of waste gases, wastewater and solid waste, and the corresponding treatment requirements. These considerations help promote safer, more environmentally responsible and sustainable manufacturing processes.

Pilot-scale production is a critical link between laboratory research and full-scale industrial manufacturing. Based on the process developed during small-scale trials, pilot production evaluates the process using equipment and facilities operating at a larger scale. As production volume increases, factors such as heat transfer, mass transfer, mixing efficiency, reaction control and equipment differences may affect process performance. Pilot-scale studies are therefore essential for identifying and resolving issues that may not be apparent during laboratory experiments and for generating reliable data to support the design of commercial manufacturing facilities.

The main objectives of pilot-scale production include verifying whether the process remains suitable and stable under scale-up conditions, evaluating the economic performance of individual reaction steps and unit operations, establishing critical process parameters, and developing quality standards and analytical methods for intermediates and finished APIs. Multiple representative batches are generally required to assess process consistency and batch-to-batch reproducibility. Some projects may use at least three to five batches for this purpose, although the appropriate number should be determined according to product characteristics, process risks and applicable regulatory requirements.

Other important activities include calculating manufacturing costs and material consumption, evaluating the recovery and reuse of reagents and solvents, improving waste treatment measures, and preparing detailed process instructions, safety procedures and production records.

Pilot-scale facilities play an important role in translating research outcomes into industrial applications. By validating processes, equipment and quality control methods under conditions closer to actual manufacturing, companies can reduce the uncertainties associated with scale-up and prepare for facility design, equipment selection, process validation and commercial production.

Regulatory compliance is fundamental to the lawful manufacture and market entry of APIs. Its core requirements include establishing a comprehensive quality management system and ensuring that manufacturing activities consistently comply with Good Manufacturing Practice (GMP) and other applicable regulatory requirements.

From a quality management perspective, manufacturers need to establish a comprehensive control system covering raw material procurement and acceptance, in-process controls, intermediate testing, finished product testing and product release. Appropriate quality specifications should be established for critical quality attributes, including purity, impurity profiles, crystal form and particle size. These specifications must be supported by suitable analytical methods that have been appropriately validated or qualified, helping ensure that product quality remains controlled and consistent across batches.

From a manufacturing perspective, GMP requires systematic management of facilities, equipment, personnel training, material handling, production operations, documentation, deviation management, change control and quality risk management. Since December 1, 2019, China has abolished the previous GMP certification system. Regulatory oversight has shifted toward ongoing supervision and inspection by drug regulatory authorities to assess manufacturers' continued compliance with GMP requirements. Inspection findings are generally classified according to the severity of identified deficiencies, with corresponding regulatory measures taken based on the inspection conclusions. For chemical APIs, manufacturers must also fulfill applicable GMP compliance inspection and manufacturing quality management requirements in accordance with the relevant registration and regulatory framework. Where contract manufacturing is involved, the manufacturing site must have the necessary production capabilities and compliance systems in place.

Following process development and the establishment of an appropriate quality system, API manufacturers must complete regulatory registration in accordance with the requirements of their target markets. In China, API regulation has moved toward a registration and review model that is closely linked to the review of finished drug products. API registrants generally need to submit registration information through the relevant platform of the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA), together with technical documentation prepared in the Common Technical Document (CTD) format where applicable. API and finished drug reviews are linked, and the relevant API is subject to associated review during the evaluation of the finished product application. Actual review timelines vary depending on the product category, application pathway and review procedure.

According to the regulatory information cited in the original article, on June 30, 2026, the NMPA issued Announcement No. 25, specifying that, effective August 1, 2026, marketing authorization applications for four categories of chemical APIs may qualify for priority review and approval. These include: chemical APIs associated with finished drug products already included in the priority review and approval program; products that are manufactured only overseas and are submitted for independent review and approval by the first domestic manufacturer seeking domestic production; overseas-manufactured chemical APIs currently used in the production of original drugs approved for marketing in China, where an application is submitted for import approval or transfer of manufacturing to China; and products identified by relevant departments of the State Council as being in market shortage. This policy is expected to streamline the review process for eligible chemical APIs.

For manufacturers targeting international markets, additional registration documents may be required depending on the regulations of each destination country or region. For APIs intended for the European market and other applicable markets, manufacturers may apply for a Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP), issued by the European Directorate for the Quality of Medicines and HealthCare (EDQM), where applicable. For the US market, companies generally submit a Drug Master File (DMF) to the US Food and Drug Administration (FDA), depending on the product and regulatory pathway. Type II DMFs primarily cover drug substances, drug substance intermediates and related materials. It is important to note that CEP and DMF are different regulatory and technical documentation mechanisms. Neither should be regarded as a universal marketing authorization or a standalone market entry license. Manufacturers must still meet the specific regulatory requirements of each target market.

Industrial-scale manufacturing marks the transition from research and development to commercial application. At this stage, manufacturers transfer the established process to full-scale production facilities and integrate equipment configuration, production planning, process control and quality management to achieve consistent, efficient and compliant batch production. Commercially manufactured APIs may be supplied to downstream pharmaceutical manufacturers for finished dosage form production or sold as API products in domestic and international markets. Process optimization, equipment suitability, manufacturing efficiency, product consistency and cost control are among the key factors determining commercial competitiveness.

As global pharmaceutical manufacturing becomes increasingly specialized, more pharmaceutical companies are optimizing their resource allocation through outsourced manufacturing and development partnerships. This has created opportunities for Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs). For API manufacturers with strong technical development capabilities, established quality management systems and reliable production capacity, participating in the customized development and manufacturing of APIs for innovative and patented drugs may provide an important opportunity to expand into higher-value business segments.

Overall, the journey from API development to commercialization is not simply a manufacturing process. It is an integrated industrial chain involving research and development, process scale-up, quality management, regulatory registration and commercial production. Laboratory research determines whether a compound can be prepared; small-scale trials explore how to make the process suitable for industrial application; pilot-scale production verifies its stability and economic feasibility after scale-up; regulatory compliance ensures that quality and manufacturing systems meet applicable requirements; registration determines whether the product can enter its target market; and industrial-scale manufacturing ultimately enables reliable supply and commercial value creation.

For API manufacturers, the effective integration of development data, process parameters, quality specifications and manufacturing management systems across every stage is essential to reducing industrialization risks, improving product quality and supply reliability, and building long-term competitiveness in domestic and international markets.